Evidence map›Paper›PMID 26133610›Full record

ArticleMedical physics2015

Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Brian W Miller, Sofia H L Frost, Shani L Frayo, Aimee L Kenoyer, Erlinda Santos, Jon C Jones, Damian J Green, Donald K Hamlin, D Scott Wilbur, Darrell R Fisher and 4 more

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Medical physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Review
  3. PretargetedTheranostics · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralization.Translational research : the journal of laboratory and clinical medicine · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Brian W MillerPacific Northwest National Laboratory, Richland, Washington 99354 and College of Optical Sciences, The University of Arizona, Tucson, Arizona 85719.
Sofia H L FrostFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Shani L FrayoFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Aimee L KenoyerFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Erlinda SantosFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Jon C JonesFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Damian J GreenFred Hutchinson Cancer Research Center, Seattle, Washington 98109 and Department of Medicine, University of Washington, Seattle, Washington 98195.
Donald K HamlinDepartment of Radiation Oncology, University of Washington, Seattle, Washington 98195.
D Scott WilburDepartment of Radiation Oncology, University of Washington, Seattle, Washington 98195.
Darrell R FisherDade Moeller Health Group, Richland, Washington 99354.
Johnnie J OrozcoFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Oliver W PressFred Hutchinson Cancer Research Center, Seattle, Washington 98109 and Department of Medicine, University of Washington, Seattle, Washington 98195.
John M PagelFred Hutchinson Cancer Research Center, Seattle, Washington 98109 and Department of Medicine, University of Washington, Seattle, Washington 98195.
Brenda M SandmaierFred Hutchinson Cancer Research Center, Seattle, Washington 98109 and Department of Medicine, University of Washington, Seattle, Washington 98195.
Fred Hutch Cancer Center · USUniversity of Washington · USPacific Northwest National Laboratory · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Thomas James Lynch · 1985 to 2026
$296.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOOLEY, TED A · 1999 to 2025
$46.1M
TREATMENT OF B-CELL LYMPHOMAP01CA044991 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRESS, OLIVER W. · 1988 to 2015
$29.3M
CENTER FOR GAMMA RAY IMAGINGP41EB002035 · NIBIB · UNIVERSITY OF ARIZONA · PI BARRETT, HARRISON H, FURENLID, LARS R · 2003 to 2018
$17.7M
Project 3: Gene Therapy for Correction of Blood DisordersP01HL122173 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STORB, RAINER F. · 2015 to 2019
$12.9M
Radioimmunotherapy Combinations for B-cell MalignancyR01CA076287 · NCI · UNIVERSITY OF WASHINGTON · PI GREEN, DAMIAN J. · 1998 to 2025
$8.1M
Alpha Radioimmunotherapy for Lymphoma TreatmentR01CA172582 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 2013 to 2018
$3.2M
CD45 Pretargeted Radioimmunotherapy for AMLR01CA109663 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRESS, OLIVER W. · 2004 to 2013
$2.9M
CD38 Pretargeted Radioimmunotherapy for MyelomaR01CA154897 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GREEN, DAMIAN J. · 2011 to 2015
$1.8M
Bispecific Antibody Engineering for AML RITR01CA136639 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRESS, OLIVER W. · 2009 to 2013
$1.6M
NCI NIH HHS P01 CA044991NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA076287NCI NIH HHS R01 CA109663NCI NIH HHS R01 CA136639NCI NIH HHS R01 CA154897NCI NIH HHS R01 CA172582NCI NIH HHS R01CA172582NHLBI NIH HHS P01 HL122173NIBIB NIH HHS P41 EB002035NIBIB NIH HHS P41EB002035
6 · The paper itself

Abstract

purposeAlpha-emitting radionuclides exhibit a potential advantage for cancer treatments because they release large amounts of ionizing energy over a few cell diameters (50-80 μm), causing localized, irreparable double-strand DNA breaks that lead to cell death. Radioimmunotherapy (RIT) approaches using monoclonal antibodies labeled with α emitters may thus inactivate targeted cells with minimal radiation damage to surrounding tissues. Tools are needed to visualize and quantify the radioactivity distribution and absorbed doses to targeted and nontargeted cells for accurate dosimetry of all treatment regimens utilizing α particles, including RIT and others (e.g., Ra-223), especially for organs and tumors with heterogeneous radionuclide distributions. The aim of this study was to evaluate and characterize a novel single-particle digital autoradiography imager, the ionizing-radiation quantum imaging detector (iQID) camera, for use in α-RIT experiments.

methodsThe iQID camera is a scintillator-based radiation detection system that images and identifies charged-particle and gamma-ray/x-ray emissions spatially and temporally on an event-by-event basis. It employs CCD-CMOS cameras and high-performance computing hardware for real-time imaging and activity quantification of tissue sections, approaching cellular resolutions. In this work, the authors evaluated its characteristics for α-particle imaging, including measurements of intrinsic detector spatial resolutions and background count rates at various detector configurations and quantification of activity distributions. The technique was assessed for quantitative imaging of astatine-211 ((211)At) activity distributions in cryosections of murine and canine tissue samples.

resultsThe highest spatial resolution was measured at ∼20 μm full width at half maximum and the α-particle background was measured at a rate as low as (2.6 ± 0.5) × 10(-4) cpm/cm(2) (40 mm diameter detector area). Simultaneous imaging of multiple tissue sections was performed using a large-area iQID configuration (ø 11.5 cm). Estimation of the (211)At activity distribution was demonstrated at mBq/μg-levels.

conclusionsSingle-particle digital autoradiography of α emitters has advantages over traditional film-based autoradiographic techniques that use phosphor screens, in terms of spatial resolution, sensitivity, and activity quantification capability. The system features and characterization results presented in this study show that the iQID is a promising technology for microdosimetry, because it provides necessary information for interpreting alpha-RIT outcomes and for predicting the therapeutic efficacy of cell-targeted approaches using α emitters.

Indexed as

Gamma CamerasAnimalsAntigens, CD20AstatineAutoradiographyDogsEquipment DesignFemaleLeukocyte Common AntigensLymph NodesLymphoma, Non-HodgkinMiceMice, NudeNeoplasm TransplantationPhantoms, ImagingRadiographyAntigens, CD20AstatineLeukocyte Common Antigens

Identifiers

PMID26133610
PMCPMC4464071
OpenAlexW2097620041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.